Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...

Mechanism of Angiogenesis

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...

Metastasis

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

RB1 inactivation in cutaneous carcinomas.

Histopathology·2025

Same author

MEK5/ERK5 inhibition sensitizes NRAS-mutant melanoma to MAPK-targeted therapy by preventing Cyclin D/CDK4-mediated G1/S progression.

Cell death & disease·2025

Same author

Optimization of Adcitmer, a Monomethyl-Auristatin E bearing antibody-drug conjugate for the treatment of CD56-expressing cancers.

Journal for immunotherapy of cancer·2025

Same author

Intratumoural programmed cell death protein expression in 92 patients with atypical fibroxanthoma and pleomorphic dermal sarcoma.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024

Same author

Short- and long-term immunosuppressive effects of melanoma influence the prognostic value of the sentinel lymph node status.

European journal of cancer (Oxford, England : 1990)·2024

Same author

Early versus late response to PD-1-based immunotherapy in metastatic melanoma.

European journal of cancer (Oxford, England : 1990)·2024

Search research articles

Related Experiment Video

Updated: Jun 26, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

CD147 impacts angiogenesis and metastasis formation.

Heike Voigt¹, Claudia S Vetter-Kauczok, David Schrama

¹Department of Dermatology, Julius-Maximilians-University, Würzburg, Germany.

Cancer Investigation

|January 23, 2009

Summary

CD147 promotes melanoma metastasis and angiogenesis. Silencing CD147 in B16 melanoma cells reduced metastasis and vascular endothelial growth factor (VEGF) expression, indicating CD147

More Related Videos

CAM-Delam Assay to Score Metastatic Properties by Quantifying Delamination and Invasion Capacity of Cancer Cells

CAM-Delam Assay to Score Metastatic Properties by Quantifying Delamination and Invasion Capacity of Cancer Cells

Published on: June 2, 2022

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Related Experiment Videos

Last Updated: Jun 26, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

CAM-Delam Assay to Score Metastatic Properties by Quantifying Delamination and Invasion Capacity of Cancer Cells

CAM-Delam Assay to Score Metastatic Properties by Quantifying Delamination and Invasion Capacity of Cancer Cells

Published on: June 2, 2022

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Area of Science:

Molecular Biology
Cancer Research
Oncology

Background:

CD147 is frequently overexpressed in various cancer cells.
Its association with tumor invasiveness and metastasis is linked to the induction of matrix metalloproteinases (MMPs).
However, MMP-2 and MMP-9 expression in the B16 melanoma model is independent of CD147.

Purpose of the Study:

To investigate the specific role of CD147 in metastasis and angiogenesis within the B16 melanoma murine model.
To determine if CD147's pro-metastatic effects are mediated through MMP induction in this context.

Main Methods:

Stable knockdown of CD147 expression in B16 melanoma cells.
Assessment of metastasis formation to draining lymph nodes in vivo.
Evaluation of vascular endothelial growth factor (VEGF) expression and blood vessel formation (angiogenesis).

Main Results:

CD147 knockdown significantly reduced the metastatic potential of B16 melanoma cells to lymph nodes.
Silencing CD147 led to decreased in vivo VEGF expression.
Reduced blood vessel formation was observed in CD147-knockdown tumors.

Conclusions:

In the B16 melanoma model, CD147 promotes metastasis.
CD147 facilitates metastasis primarily through the induction of angiogenesis, independent of MMP activity.
Targeting CD147 may offer a therapeutic strategy to inhibit melanoma metastasis by disrupting angiogenesis.